Technical Analysis for POAI - Predictive Oncology Inc.

Grade Last Price % Change Price Change
C 1.47 0.00% 0.00
POAI closed unchanged on Friday, February 26, 2021, on 64 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical POAI trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Fell Below 20 DMA Bearish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -6.37%
Calm After Storm Range Contraction -6.37%
NR7 Range Contraction -6.37%
Wide Bands Range Expansion -6.37%
Fell Below 20 DMA Bearish -1.34%
MACD Bearish Signal Line Cross Bearish -1.34%
Older End-of-Day Signals for POAI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Predictive Oncology Inc. Description

Predictive Oncology (formerly Precision Therapeutics Inc.) (Nasdaq: AIPT until June 12, 2019; POAI starting June 13, 2019) operates through its three business units, Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.


Classification

Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Biotechnology Cancer Clinical Medicine Pharmaceutical Artificial Intelligence Oncology Irrigation Ovarian Cancer Cell Biology Genomics FDA Tumors Biomarker Cancer Cell Precision Medicine Targeted Therapy Informatics Cancer Therapies Biomarkers Bioinformatics Proteomics Patient Specific Tailored Solution

Is POAI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.42
52 Week Low 0.63
Average Volume 4,698,460
200-Day Moving Average 1.18
50-Day Moving Average 1.17
20-Day Moving Average 1.57
10-Day Moving Average 1.71
Average True Range 0.24
ADX 48.04
+DI 28.66
-DI 21.48
Chandelier Exit (Long, 3 ATRs ) 1.58
Chandelier Exit (Short, 3 ATRs ) 1.76
Upper Bollinger Band 2.14
Lower Bollinger Band 1.00
Percent B (%b) 0.41
BandWidth 72.33
MACD Line 0.12
MACD Signal Line 0.18
MACD Histogram -0.0581
Fundamentals Value
Market Cap 25.98 Million
Num Shares 17.7 Million
EPS -0.43
Price-to-Earnings (P/E) Ratio -3.46
Price-to-Sales 4.75
Price-to-Book 1.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.77
Resistance 3 (R3) 1.76 1.64 1.72
Resistance 2 (R2) 1.64 1.57 1.65 1.70
Resistance 1 (R1) 1.56 1.52 1.57 1.57 1.69
Pivot Point 1.44 1.44 1.45 1.45 1.44
Support 1 (S1) 1.36 1.37 1.37 1.37 1.25
Support 2 (S2) 1.24 1.32 1.25 1.24
Support 3 (S3) 1.16 1.24 1.22
Support 4 (S4) 1.17